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The entry of viruses into host cells is one of the key processes
of infection. The mechanisms of cellular entry for enveloped
virus have been well studied. The fusion proteins as well as the
facilitating cellular lipid factors involved in the viral fusion entry
process have beenwell characterized. The process of non-envel-
oped virus cell entry, in comparison, remains poorly defined,
particularly for large complex capsid viruses of the family Reo-
viridae, which comprises a range of mammalian pathogens.
These viruses enter cells without the aid of a limitingmembrane
and thus cannot fuse with host cell membranes to enter cells.
Instead, these viruses are believed to penetrate membranes of
the host cell during endocytosis. However, themolecular mech-
anism of this process is largely undefined. Here we show, utiliz-
ing an in vitro liposome penetration assay and cell biology, that
bluetongue virus (BTV), an archetypal member of the Reoviri-
dae, utilizes the late endosome-specific lipid lysobisphospha-
tidic acid for productive membrane penetration and viral entry.
Further, we provide preliminary evidence that lipid lysobispho-
sphatidic acid facilitates pore expansion duringmembrane pen-
etration, suggesting amechanism for lipid factor requirement of
BTV. This finding indicates that despite the lack of amembrane
envelope, the entry process of BTV is similar in specific lipid
requirements to enveloped viruses that enter cells through the
late endosome. These results are the first, to our knowledge, to
demonstrate that a large non-enveloped virus of the Reoviridae
has specific lipid requirements for membrane penetration and
host cell entry.
Cell entry of viruses is a key stage that initiates infection.
During this process, virusesmust breach themembrane barrier
that encompasses cellular contents (1–3). The site of virus
membrane penetration is specific to each virus; however, the
majority of viruses enter the cytosol via the endocytic compart-
ments of host cells (4, 5). In this environment, acidic pH triggers
virus fusion proteins that mediate virus entry into the host cell
cytosol. This process has been particularly well characterized in
enveloped viruses that enter the host cytosol by fusing their
own limiting membrane with that of the host cell, thereby
releasing viral contents to initiate the infection cycle (6–8).
Non-enveloped viruses do not possess a limiting membrane
and as such must traverse the membrane barrier of the cell by
an alternative mechanism. This process is well understood for
small non-enveloped viruses, such as members of the Picorna-
viridae, inwhich evidence suggests that small amphipathic pep-
tides insert and form a discrete pore in the host membrane
through which viral contents are extruded (9–13). For larger
non-enveloped viruses, such as those of the Reoviridae, the
mechanism of host cell membrane disruption remains poorly
defined. The Reoviridae comprises a large family of non-envel-
oped viruses whose capsids are complex and encapsidate a seg-
mented double-stranded RNA genome (14). These viruses ini-
tiate host cell infection by delivering a large core particle into
the host cell cytosol; however, the mechanism by which these
large particles traverse the cellular membrane barrier remains
poorly understood. Several members of the Reoviridae have
been shown to enter the cell cytosol via the early-late endocytic
compartments. Although some insights have been gained into
the process of penetration bymammalian Reovirus and Rotavi-
rus, these studies have been conductedwithmembranes that do
not accurately represent the membrane environment present
during trafficking through the cellular endocytic compart-
ments (15–18). BTV2 is an archetypal member of theOrbivirus
genus of the family Reoviridae. BTV consists of 27 serotypes
(19) and is an agriculturally significant arbovirus that causes a
hemorrhagic disease in undulates, predominantly in sheep (20,
21); however, recent outbreaks of BTV serotype 8 have also
shown pathogenicity in domestic cattle herds (22, 23). The
virus consists of three concentric layers of protein (24, 25) with
the innermost layers of VP3 andVP7 delimiting the structure of
the core particle (26–28) that enters the host cytosol (29). The
outer layer of the virus capsid is composed of VP2 and VP5
proteins (30) that facilitate virus entry and delivery of the core
particle into the host cell cytosol (31). VP2 has been shown to
act as a receptor-binding protein, which binds sialic acid (32,
33) and facilitates clathrin-mediated endocytosis of the viral
particle that is trafficked into the endosomal compartments of
the cell (34). VP5 acts as an acid-dependent membrane pene-
tration protein that penetrates the host cell membrane (35) and
delivers the core particle into the host cytosol, wherein tran-
scription of the viral genome commences (36). How this pro-
tein penetrates cellular membranes and which membrane fac-
tors facilitate this process are poorly characterized.
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Here, using BTV as amodel system, we investigate themem-
brane composition involved in VP5 membrane penetration.
Using an in vitro liposome penetration assay, we demonstrate
that VP5 penetrates liposomes of a late endosome (LE), but not
early endosome (EE), membrane composition and that this is
due to the late endosome-specific lipid factor 2,2-dioleoyl lyso-
bisphosphatidic acid (LBPA). We demonstrate that this VP5-
dependent penetration process is probably due to a combina-
tion of anionic charge and fluidic properties of LBPA. Further,
we show that VP5 forms pores of a discrete size and that LBPA
may allow VP5 membrane pore expansion in a concentration-
dependent manner. We corroborate these in vitro findings
pharmacologically in in vivo virus infection,which suggests that
BTV enters via the LE compartment because its membrane
composition allows efficient pore formation for core delivery to
the host cell cytosol. These findings demonstrate a specific reli-
ance of a non-enveloped virus on a host lipid factor for cell
entry, due to its biophysical properties. This relationship may
hold true for other non-enveloped viruses that deliver large
cargos into the host cytosol, presenting a novel therapeutic ave-
nue for infection prophylaxis of these virus types.
Experimental Procedures
Cell Lines and Virus Stocks—BSR, HeLa, and PT cells were
maintained as described previously (37, 38). Spodoptera fru-
giperda (Sf9) cells were grown in InsectExpress (Lonza)
medium supplemented with 2% (v/v) fetal calf serum and incu-
bated either in suspension or in monolayer cultures at 28 °C.
Recombinant Autographa californica nuclear polyhedrosis
viruses were produced by co-transfecting pTriExHMBPVP5
WT or mutant plasmid and Bacmid:KO orf1629 (39). Expres-
sion cultures were maintained as described previously (35).
Antibodies, Reagents, and Plasmids—Polyclonal antibodies
were used for detection of viral proteins NS1 (produced in
mouse) and NS2 and VP5 (produced in guinea pig); these were
produced in house. For detection of LBPA, a mouse monoclo-
nal antibody, anti-LBPA antibody (6C4), in cell supernatant
(Z-SLBPA) was purchased from Echelon Biosciences Inc. for
the detection of LBPA. A rabbit polyclonal antibody, anti-
GAPDH (ab9485), and a polyclonal anti-Lamp1 rabbit antibody
(ab24170-100) were purchased from Abcam. For antibody
uptake blocking assays, a purified version of the monoclonal
anti-LBPA antibody (P-SLBPA) (Echlelon Biosciences Inc.) and
a monoclonal anti-FLAG M2 mouse antibody (Sigma-
Aldrich) were utilized. Hoechst 33342 was purchased from Life
Technologies, Inc. Alexa 488- and 594-conjugated secondary
antibodies were purchased fromLife Technologies andAbcam,
respectively. Alkaline phosphatase-conjugated goat anti-
mouse, anti-rabbit, and anti-guinea pig polyclonal antibodies
were obtained from Sigma-Aldrich. Paraformaldehyde, BSA,
Triton X-100, alkaline phosphatase liquid ELISA substrate,
DMSO, and U18886A inhibitors were purchased from Sigma-
Aldrich. Calcein and fluorescent dextrans of 4, 10, and 20 kDa
were purchased from Sigma-Aldrich. Lipids phosphatidylcho-
line (PC), phosphatidylethanolamine, sphingomyelin, phos-
phatidylinositol, phosphatidylserine (PS), LBPA, and Avanti
Mini-Extruder were purchased from Avanti Polar lipids.
0.1-m Nuclepore Track-Etched Membranes polycarbonate
membrane filters were purchased fromWhatman. The pTriEx-
HMBP-TEV-VP5 transfer vector was constructed by cloning
the coding region of BTV-1VP5 into a BamHI site of a premade
(in house) empty pTriExHMBP-TEV vector in which cloning
into a BamHI site places the gene of interest in-frame with and
upstream of the HMBP-TEV cassette for which the GS of the
ENLYFQGSTEV site represents the in-frame translation of the
BamHI restriction site.
Recombinant VP5 Expression and Purification—BTV-1 VP5
(accession numberACR58462) proteins were expressed using a
recombinant baculovirus system in Sf9 cells. Recombinant VP5
was expressed as an N-terminally tagged His6-MBP fusion pro-
tein with a glycine-serine linker and a TEV cleavage site.
Expression cultureswere harvested 50 hpostinfection, and cells
were lysed by Dounce homogenization in lysis buffer (20 mM
Tris, 150mMNaCl, 20mM imidazole, 1% Triton X-100, pH 8.5)
supplemented with EDTA-free protease inhibitor mixture
(Sigma-Aldrich), and lysate was clarified by centrifugation. Sol-
uble lysate was purified using an Äkta Explorer FPLC unit (GE
Healthcare), first utilizing immobilized metal affinity chroma-
tographywith a 5-mlHisTrapHP column (GEHealthcare) and,
second, affinity chromatography using a 1-ml MBPTrap HP
column (GE Healthcare). Eluted proteins were concentrated to
200l and cleavedwith 20g of TEV protease (Sigma-Aldrich)
overnight at 4 °C. Cleaved tags and proteases were removed
using immobilized metal affinity chromatography. Typically,
0.5 mg of pure WT VP5 was produced per 200 ml of culture.
Mutant proteinswere producedby site-directedmutagenesis of
WT expression constructs. Primers were phosphorylated using
polynucleotide kinase (New England Biolabs), and forward
primers Mutant1 (5-GATGGGTCTAGTCATACTGTCCT-
TAAACCGATTTGGCAAAAG-3), Mutant2 (5-GATGGG-
TCTAGTCATACTGTCCTTAAACCTATTTGGCCTA-
CTGGTAGGCAACGCGTTAACTTCTAATAC-3), and
Mutant3 (5-GATGGGTAAAGTCATACGGTCCTTAAAC-
CTATTTGGCCTACTGGTAGGCAACGCGTTAACTTCT-
AATAC-3) were utilized in conjunction with the reverse
primer mut rev (5-TTCGCTAAGGGCGCACTTTTTAAC-
3) to amplify WT BTV-1 VP5 (accession number ACR58462)
pUC19T7plasmid (boldface lettering indicatesmutation sites).
The products were DpnI (New England Biolabs)-digested and
then ligated and transformed. Mutations were confirmed by
Sanger sequencing and used as theywere for reverse genetics or
mutant ORFs cloned into the pTriExHMBP-TEV vector for
protein expression.
Liposome Production—A total of 5 mg of lipids (Avanti Polar
Lipids) with a composition of early or late endosomal mem-
branes (see Table 1) in chloroformwere dried under vacuum to
give a solvent-free film. This was either hydrated in 1 ml of
Calcein (Sigma-Aldrich) buffer (50 mM calcein, 100 mM NaCl,
2.7 mM KCl, 10 mM Na2HPO4, 1.8 mM KH2PO4, pH 7.5) or, for
fluorescent dextrans (Sigma-Aldrich), PBS buffer (137 mM
NaCl, 2.7 mM KCl, 10 mM Na2HPO4 1.8 mM KH2PO4 pH 7.5)
plus dextran at a concentration of 200 mgml1. Mixtures were
subsequently freeze-thawed three times with brief vortexing
after each thaw. The lipid suspensions were then extruded 11
times through a 0.1-mpolycarbonatemembrane filter (What-
man) using a Mini Extruder (Avanti Polar Lipids). Unencapsu-
BTV Entry and Cellular Lipid
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lated calcein and fluorescent dextran were removed from the
extruded suspension by size exclusion chromatography using
Sephadex G-75 resin (Sigma-Aldrich), whereas PBS, pH 7.5
(liposome buffer) was used as the aqueous phase buffer. Lipo-
somes were stored at 4 °C and used within 1 week of creation.
Pore Formation Assay—Purified WT and mutant VP5 pro-
teins were reconstituted in PBS, pH 7.5, containing 1 g/ml
anti-gp64 monoclonal antibody B12D5 (liposome buffer). Cal-
cein or dextran-loaded liposomes and VP5 protein were mixed
in a flat black 96-well plate (Griener) and incubated at room
temperature for 10 min at a final concentration of 0.1 mg/ml
VP5 and 0.1 mg/ml total lipid for liposomes. Mixtures were
then acidified to the stated pH levels using a predetermined
titration of 0.1 N HCl and incubated at 37 °C for 30 min. Fluo-
rescence was then measured with a SpectraMax M5 plate
reader (Molecular Devices) using top read mode with an exci-
tation/emission of 485/535 nm.All liposomedatawere normal-
ized to complete calcein release control using Triton X-100
buffer and buffer alone, which included the gp64 antibody.
Normalized percentage calcein or dextran release was calcu-
lated using the formula, R% (R R0)/(R100 R0), where R%
is percentage release, R is the measured fluorescence, R0 is the
measured fluorescence of liposomes acidifiedwith buffer alone,
andR100 is the fluorescence of liposomeswith buffer containing
0.1% Triton X-100. Experiments were performed in triplicate.
ReverseGenetics—VP5mutants were created by site-directed
mutagenesis ofWTBTV-1VP5 (accession numberACR58462)
pUC19 T7 plasmid. Reverse genetics was performed as
described previously (40) and repeated three times. In all cases,
only WT virus was recovered.
Cholesterol Transport Inhibitor U18666A Treatment of Viral
Infection—1  104 HeLa or PT cells/well of a 96-well culture
dish were incubated for 2 h with medium containing 30 M
U18666A, a non-toxic concentration, by trypan blue staining.
Subsequently, wells were washed with serum-free drugged or
mock-treated (drug carrier buffer) medium. Cells were syn-
chronously infected with BTV-1 in serum-free drugged or
mock-treated medium at an MOI of 0.1, 1, or 5. After virus
adsorption, cells were washed twice and then incubated with
drug- or mock-treated medium for a further 3 h at 35 °C, after
which medium was replaced with drug-free medium. Plates
were further incubated at 35 °C for 9 h, after which wells were
washed and fixed with 4% formaldehyde in PBS at room tem-
perature for 15 min.
Antibody Endocytosis-blocking Assay—1  104 HeLa cells/
well of a 96-well culture dishwere incubatedwithmedium con-
taining 50gml1 of an anti-LBPAmouse antibody or isotype-
matched control anti-FLAG antibody (Sigma-Aldrich) for 18 h.
Cells were then washed and synchronously infected with
BTV-1 at an MOI of 1. After virus adsorption, infected cells
were washed and incubated in fresh medium at 35 °C for 12 h,
after which cells were fixed as for drug-treated cells.
Western Blotting Analysis—SDS-polyacrylamide gels were
transferred via a semidry blotter to PVDF transfer membranes
and blocked for 4 h with TBS-T containing 10% (w/v) milk
powder. Primary antibodies for the detection of NS1 and NS2
were rabbit anti-NS1 serum and guinea pig anti-NS2 serum,
and commercial rabbit anti-GAPDH (Abcam, ab9485) was
used for GAPDH. Blot images were imported into ImageJ soft-
ware for densitometry analysis. The background intensity was
subtracted from the images. Bands were then selected by draw-
ing a tight boundary around them. Intensities of the selected
bands were then exported into an Excel format. NS1 and NS2
values were normalized to the correspondingGAPDHvalues to
generate NS1 or NS2/GAPDH ratios for each sample for fur-
ther statistical analyses.
Immunoperoxidase Assay—Fixed cells in a 96-well format
were blocked and permeabilized by incubation with blocking
buffer (PBS, 1% (w/v) BSA, 0.1%Triton X-100) for 1 h. Amouse
primary antibody (produced in this laboratory) to the viral non-
structural protein antigen NS1 was then bound (1:300 dilution)
by incubating wells for 1 h at room temperature. Subsequently,
cells were washed three times, and a secondary alkaline phos-
phatase conjugate anti-mouse IgG secondary antibody (1:500
dilution) (Sigma-Aldrich) was bound for 1 h at room tempera-
ture. Cells were subsequently washed, followed by the addition
of alkaline phosphatase yellow (p-nitrophenyl phosphate) liq-
uid substrate (Sigma-Aldrich) to each well. Signal was devel-
oped at room temperature for 20 min, after which the reaction
was stopped by the addition of NaOH. Plates were then read at
an absorbance of 405 nm with a SpectraMaxM5 plate reader
(MolecularDevices) using top readmode.Averaged signal from
uninfected and cells was subtracted from the data, and percent-
age infectivity was calculated by normalizing to infected mock-
treated cells.
Confocal Microscopy—Confocal microscopy was performed
by amethod similar to that ofDu et al. (38). Briefly 5 104HeLa
cells were synchronously infected with BTV-1 at anMOI of 10.
Unbound virus was subsequently washed off, and coverslips
were fixed at a time point either 0, 15, 20, or 45 min after infec-
tion. Coverslips were then processed for imaging. Slides were
imaged using a Zeiss LSM510 confocal microscope using oil
immersion with a 63 objective at room temperature. Images
were processed using a Zeiss image browser.
Virus Titration—Supernatants fromBTV-infected cells were
collected after 24 h, and relative virus titers were determined by
plaque assays on BSR cells. Briefly, cells were seeded in 12-well
plates and incubated for 45 min with diluted virus in 100 l of
serum-free DMEM. After removal of the inoculums, cells were
washed once and overlaid with 1 ml of 0.6% Avicel-containing
overlay medium containing 2% fetal bovine serum and antibi-
otics. Plaques were visualized after an incubation period of 2–3
days at 35 °C by staining with crystal violet for several hours.
Statistical Analysis—p values were calculated by unpaired t
test using GraphPad Prism 6 software.
Results
VP5 Penetrates Late Endosome-mimicking Liposomes—
Recent cell biology data indicate that BTV serotype 1 traffics
from early to late endosomal compartments, with VP2 andVP5
found both in the EE compartment and VP5 alone in the LE
compartment (38). Although this indicates the localization of
these proteins during entry, the site at which BTV core enters
into the cytosol has not clearly been demonstrated. The envi-
ronment of EE and LE compartments has been shown to vary
significantly, with each compartment displaying a unique lipid
BTV Entry and Cellular Lipid
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composition of membranes (41, 42), with an increased acidity
occurring during trafficking toward the lysosome (43–45).
Using an in vitro liposome penetration assay, it was investigated
which membrane composition of EE or LE and at which pH
VP5mediatesmembrane pore formation. Liposomeswere pro-
duced that approximated the composition of EE or LE endo-
somal membranes defined by Kobayashi et al. in 1999 (48)
(Table 1). Baculovirus-expressed purified recombinant VP5, as
described under “Experimental Procedures,” was utilized in a
liposome penetration assay with liposomes mimicking EE or
LE. Recombinant VP5 was shown to substantially penetrate
liposomes of an LE in a pH-dependentmanner with81% (p
0.001) penetration occurring between pH7.5 and 5. In addition,
the most efficient membrane penetration occurred at a late
endosomal pH 5–5.5 for LE liposomes (Fig. 1A). A small (9%)
but significant (p  0.01) penetration of liposomes mimicking
EE was observed between pH 7.5 and pH 5.We further corrob-
orated these findings by determining the pH at which the con-
formational change of VP5 occurred. VP5 was pre-acidified to
the pH values 7.5–5 (Fig. 1B) and then re-equilibrated to pH 7.5
prior to use in a liposome assay by acidification to pH 5. The
results demonstrated that the conformational change of VP5 is
irreversible and occurs substantially at pH 6.5, with maximal
conformational change occurring at a pH of the LE (Fig. 1B).
Together, these data strongly suggest that VP5 is activated at a
pH of early to late endosomal transition and can actively pene-
trate LE membranes.
Lysobisphosphatidic Acid Is Required for VP5 Late Endo-
some-mimicking Liposome Penetration—Considering the
finding that VP5 pore formation occurs in LEmembrane-mim-
icking liposomes, we subsequently investigated the lipid prop-
erties of LE membranes that allow VP5 penetration function.
The lipid composition of LE membranes is significantly
enriched in LBPA (Table 1) compared with EE. We hypothe-
sized that this major difference in lipid composition could be
the enabling factor in VP5 membrane penetration. To investi-
gate this possibility, LE-mimicking liposomes were tested in
which the LBPA contentwas decreased by substitutionwith the
zwitterionic lipid PC, which constitutes the major lipid of LE
membranes (Table 1). Results indicated a direct dependence of
VP5 membrane penetration with LBPA content (Fig. 2), sug-
gesting a role of this lipid in enabling VP5 membrane penetra-
tion. Further, we investigated the physical properties of this
lipid that could allow membrane penetration. LBPA is anionic,
which may be a contributing factor to allow VP5 membrane
pore formation. To test this, we created liposomes of a simpler
membrane composition. PS is another anionic lipid that is
found in the inner leaflet of the cytosolic membrane and to
some extent in EE and less so LE membranes (46). Liposomes
containing PC alone or PS/PC (1:3) were tested to investigate
whether the artificially high 33% anionic charge of PS in these
liposomes could also facilitate membrane penetration by VP5.
Results suggested that in a simple membrane composition, PS
was able to partly facilitate membrane penetration by VP5.
However, this was not as efficient as LE membranes (Fig. 2,
arrow), suggesting an effect of anionic charge in enabling VP5
penetration activity.
VP5 exhibits conserved positive charged residues in its two
N-terminal amphipathic helices (amino acids 1–20) that have
FIGURE 1. The pH dependence of VP5-induced calcein release from 0.1-m vesicles mimicking early and late endosomemembranes. A, purified VP5
wasmixedwith either early or late endosome-mimicking liposomes andacidified to a rangeof pHas indicated. Leakageof calcein from liposomeswas assayed,
and the results were normalized to liposomes treated or untreated with 0.1% Triton X-100. B, VP5 protein was acidified to pH 5.0–7.0, as indicated, and
subsequently dialyzed back to pH 7.5. A pore formation assay was then performed with acidification at pH 5.5. Results were normalized as in A. Results show
three independent repeats, and error bars represent S.D.
TABLE 1
Lipid compositions of EE- and LE-mimicking liposomes
PE, phosphatidylethanolamine; SM, sphingomyelin; PI, phosphatidylinositol. Mod-
ified from Ref. 48.
EE LE
% %
PC 50 50
PE 23 20
SM 9 3
PS 9 4
PI 8 8
LBPA 1 15
BTV Entry and Cellular Lipid
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previously been shown to cause membrane disruption (35).
These positive charges may interact with the anionic charge of
PS or LBPA to allow initial membrane interaction in order to
facilitate the penetration process. A recent atomic resolution
structure of VP5 provides some structural evidence supporting
this hypothesis. The structure indicates that this region of theN
terminus forms a dagger-like domain that is hypothesized to be
projected toward the host targetmembrane by an acid-induced
conformational change (47). To interrogate this, VP5 mutants
with substitutions of positive charged residues of its two helices
to hydrophobic leucine residues were created because leucine
displays the same branch length as lysine or arginine. We
designed three sets of mutants (Fig. 3A): one substituting all
positive charge in the first helix (mutant 1, K3L/R6L), one sub-
stituting positive charge in the second helix (mutant 2, R10L/
K13L/K14L), and one substituting all positive charges in both
helices (mutant 3, K3L/R6L/R10L/K13L/K14L). Thesemutants
were expressed and purified as forWTVP5 (see “Experimental
Procedures”); however, mutant 1 was poorly expressed (data
not shown) and was not included in a pore formation assay.
Mutants 2 and 3 yielded sufficient pure protein to test for pore
formation and were shown to be trimeric structures following
native PAGE analysis (data not shown). Bothmutants displayed
a significant reduction in LE liposome penetration with direct
relation to positive charge content and penetration efficiency
(Fig. 3B). The data indicate a role of ionic interactions between
the N terminus of VP5 and target membranes in facilitating
pore formation. As expected, these mutants also could not be
FIGURE 2. The late endosome lipid LBPA facilitates VP5 penetration. Late
endosome-mimicking liposomes containing a decreasing amount of LBPA
(swapped for PC) were tested in a pore formation assay with purified VP5 at pH
5.5. Significant results are indicated (*, p 0.01 compared with LE 15% LBPA).
Liposomeswith a simplified high anionic (PC/PS, 3:1) and non-anionic composi-
tion (PC alone) were also tested (*, p 0.01 compared with 1:3 PC/PS). Arrow,
penetration recoveryby includinganionicPSwithPC in the liposomemembrane
composition. Results from three independent repeats were normalized to lipo-
somes treated or untreatedwith 0.1% Triton X-100. Error bars, S.D.
FIGURE 3.Positive charged residues in theN-terminal amphipathic helix are required for late endosome liposomepenetration.A, helicalwheel plots of
the N-terminal 17 amino acids of WT andmutant VP5 constructs (M1, M2, or M3). Blue,white, and black circles represent positively charged, hydrophobic, and
glycine residues, respectively. Filled black circle, end of the sequence. Modified plots were generated from the Helical Wheel Web site. B, purified WT VP5 or
mutantsM2 andM3, lacking positive charged residues in their N-terminal amphipathic helix, were utilized in a pore formation assay as described in the legend
to Fig. 2. Significant results are indicated (*, p  0.01 compared with WT). C, effect of increasing amounts of NaCl on pore formation. Results from three
independent repeats were normalized to liposomes treated or untreated with 0.1% Triton X-100. Error bars, S.D.
BTV Entry and Cellular Lipid
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recovered by reverse genetics in three separate attempts, sug-
gesting an essential role of these positively charged residues in
virus viability. Moreover, it was hypothesized that if VP5 is
indeed interacting with LE liposomes via electrostatic forces, it
would be possible to disrupt this process by increasing the ion
content of the penetration reaction. Penetration assays were
performed with LE liposomes and WT VP5 increasing the
NaCl content of assay buffer. These results demonstrated
that WT VP5 membrane penetration was inhibited by
increasing the solvent dielectric of the assay medium (Fig.
3C), suggesting that electrostatic forces do indeed play a role
in the process of VP5 membrane penetration. The solubility
of VP5 was tested in each buffer condition by ultracentrifu-
gation, which indicated no loss of VP5 solubility in all buffers
tested (data not shown).
Given the role of ionic forces in VP5 penetration, we investi-
gated whether PS could enable VP5 membrane penetration in
the context of LE by swapping LBPA content with PS. Interest-
ingly, the results demonstrated that despite possessing anionic
charge, in the context of the more complex composition of LE
membranes, PS was unable to support penetration by VP5 (Fig.
4A). This finding suggests that additional properties of LBPA, as
well asnegativecharge,playa role inpore formationbyVP5.LBPA
has been demonstrated to increase membrane fluidity of constit-
uent membranes, potentially due to lateral forces created by its
conical profile (42).When LBPAwas swapped for PS in EE-mim-
icking liposomes, no recovery of penetration was observed (Fig.
4A). The amount of PS in these membranes is only half that of
LBPA in LE membranes, in addition to an increased sphingomy-
elin content. This increased sphingomyelin might have counter-
acted membrane fluidity of the lower concentration of LBPA in
these liposome constituents. To test whether LE membrane pen-
etration was affected by decreased membrane fluidity, LE lipo-
somes were created with increasing cholesterol content. The
results showed that increasing cholesterolwith reduction inmem-
brane fluiditydo indeeddecreaseVP5membranepenetration (Fig.
4B). Taken together, these data suggest that highmembrane fluid-
ity mediated by the physical properties of LBPA is necessary for
VP5membrane penetration.
Access to LBPA-enrichedMembranes Is Required for Produc-
tive BTV-1 Entry in Cell Culture—Our in vitro assays demon-
strated the necessity of LBPA in VP5 membrane penetration.
To confirm this finding in vivo, we investigated whether pro-
ductive BTV-1 entry required virion access to LBPA-enriched
membranes in a cell culture model.
To assess whether VP5 could possibly interact with LBPA
during virus entry, we determined whether VP5 and LBPA co-
localized at 30min postinfection (PI). LBPA is located in the LE
(48), and it has been previously shown that BTV-1 co-localizes
with the LEmarker CD63 at 30min PI (38). Cells were synchro-
nously infected with anMOI of 10 and fixed and stained at time
points 0, 15, 30, and 45 min PI, followed by double immuno-
staining of fixed HeLa cells. Results demonstrated that VP5
co-localizes with LBPA during cellular infection only at 30 min
PI (Fig. 5A, panel 30), suggesting that the virus has the potential
to interact with LBPA in cells during endocytosis. At 45min PI,
VP5 (Fig. 5A, bottom right panel) was no longer seen to co-lo-
calize with LBPA, indicating a migration out of LBPA-rich
compartments.
Co-staining for LBPA and VP7 core protein was repeated
at time points 30 and 45 min PI to detect the localization of
the core (Fig. 5B, top panels). VP7 co-localized with LBPA at
30 min but to a lesser extent at 45 min PI, indicating that a
viral core associated with VP5 was present within LBPA-rich
compartments at 30 min PI. Subsequently, we examined
whether the core (VP7) trafficked on to the lysosome by
visualizing VP7 and Lamp1 co-localization at 30 and 45 min
PI (Fig. 5B, bottom panels). Results showed a lack of substan-
FIGURE 4.VP5 pore formation requires LBPA of late endosome. A, LE- or EE-mimicking liposomes were produced as before or had PS content swapped for
LBPA (EE) or LBPA content swapped for PS (LE) as indicated and tested in a pore formation assay with purified VP5. Results were normalized to liposomes
treatedor untreatedwith 0.1%TritonX-100. Significant differences are indicated (*,p0.01 comparedwith LE 15%LBPA).B, LE liposomeswereproducedwith
the addition of increasing amounts of cholesterol and tested in a pore formation assay. Note that increasing cholesterol inhibits VP5 pore formation of LE
liposomes. Results were normalized as in A. Experiments were performed in triplicate, and significant differences are indicated (*, p  0.05; **, p  0.01
compared with LE 15% LBPA). Error bars, S.D.
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tial co-localization of Lamp1 with VP7 at both time points.
This suggested that the majority of viral cores had migrated
out of the endosomal trafficking pathway prior to reaching
the lysosome.
U18666A is an amphipathic sterol that has been demon-
strated to induce a Niemann-Pick C type disease phenotype
within treated cells, by inhibiting cholesterol transport from
lysosomal and late endosomal compartments (48, 49). Treat-
ment of HeLa cells with 30 M U18666A indicated an increase
in cholesterol of LBPA-rich membranes (data not shown). To
this effect, it was tested whether this U18666A-mediated
increase in cholesterol of LBPA membranes inhibited BTV-1
entry into both PT and HeLa cells.
In both HeLa (Fig. 6A, lanes 3 and 6) and PT (Fig. 6A, lanes 9
and 12) cells, viralNS1 andNS2protein levelswere significantly
decreased when compared with the untreated controls HeLa
(Fig. 6A, lanes 2 and 5) and PT cells (Fig. 6A, lanes 8 and 11).
Western blotting densitometry analysis showed that at anMOI
of 5, NS1 protein levels decreased in HeLa and PT cells by55
and65%, respectively, and by85 and73% at an MOI of 1
(Fig. 6B). Similarly, at anMOI of 5,NS2 protein levels decreased
in HeLa and PT cells by70 and 66%, respectively, and by87
and 83% at anMOI of 1 (Fig. 6B). Moreover, we also observed a
1 log10 decrease in virus titer in virus derived from previously
treated cells (Fig. 6C). Furthermore, we carried out an immu-
noperoxidase-based assay, where we observed comparable
decreases of NS1 (Fig. 6D), validating the assay for subsequent
use. These data show that U18666A-mediated accumulation of
cholesterol in LBPA-richmembraneswas able to inhibit BTV-1
entry of both HeLa and PT cells.
To support these findings, we used a commercially available
anti-LBPA antibody, which has been shown to be endocytosed
by cells in culture upon which it binds to LBPA in LE compart-
ments. This binding disrupts the architecture of the LE (41) and
has been shown to inhibit the entry of dengue virus, which also
utilizes LBPA (50). In a titration experiment, no effect was seen
in PT cells, potentially due to cell type-specific kinetics of anti-
body uptake. HeLa cells were incubated for 12 h in medium
containing 50 g ml1 anti-LBPA or isotype-matched anti-
FLAG antibody control or left untreated. After 12 h, medium
was removed, and cellswerewashed and infectedwithBTV-1 at
an MOI of 1. Cells were then fixed 12 h PI, and expression of
NS1 protein was quantified by an immunoperoxidase assay. A
reduction in NS1 expression was observed by preincubation
with anti-LBPA antibody, supporting a specific role of this lipid
in BTV-1 entry (Fig. 7). Taken together with in vitro observa-
tions, these results indicate that membrane fluidity plays a sig-
nificant role in BTV-1 entry of cells.
To exclude the possibility that the U18666A-mediated accu-
mulation of cholesterol in LBPA-rich membranes could inter-
fere with viral replication postentry, both HeLa and PT cells
were treated with U18666A 4 h PI (Fig. 8A). Western blotting
densitometry analyses revealed that regardless of MOI or cell
line used, therewas no significant decrease in eitherNS1orNS2
protein levels, as had been observed during entry (Fig. 8B). Fur-
ther, U18666A treatment did not affect virus titer (Fig. 8C).
LBPA May Facilitate VP5 Pore Expansion—Based on our
findings that VP5 penetrates LE-mimicking liposomes and that
inhibition of access to LBPA membranes in cell culture inhib-
ited BTV-1 entry, we next sought to analyze whether the pore
formed in LE membranes could support core entry to the host
cytosol. Because cell culture data supported the results derived
from our in vitro assay system, it was deemed to be robust
enough to draw conclusions about the nature of the pore
formed by VP5 during cell entry. To this end, pore formation
assays with LE liposomes andWT VP5 were performed, utiliz-
ing liposomes containing entrapped fluorescent dextrans of
specific sizes. We utilized LE liposomes containing dextrans of
4, 10, and 20 kDa as well as the small molecule calcein as a
FIGURE 5.Co-localizationofVP5andVP7with LBPA inBTV-infected cells.
HeLa cells were fixed at 0, 15, 30, or 45min postinfection. A, co-localization of
VP5 (red) and LBPA (green). B, co-localization of VP7 (red) and LBPA (green, top
panels) or Lamp1 (green, bottom panels). Inset in 30-min panels, an enlarged
region of co-localization indicated by awhite arrow. Bars, 10 m.
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positive control. In a VP5 penetration assay, LE liposomes were
only capable of releasing calcein and 4-kDa dextran, suggesting
that VP5 formed a discrete pore (Fig. 9A). The Stokes radii of
these dextrans would place the diameter of the pore at 14 Å
and23 Å in size. Because there are 120 trimers of VP5 in each
virion particle, this could provide sufficient local destabilization
of the LE membrane to allow core egress. If calculated with the
lowest assumption of 14-Å pore size diameter, the additive
diameter of pores is 168 nm, sufficiently large for the diameter
of the core, which is 70 nm; however, these trimers are not
arranged linearly. It may be that concentrated local destabiliza-
tion of the LEmembrane is sufficient to facilitate the process of
core egress.
Given the evidence that LBPA is key to the process of VP5
pore formation, we finally investigated whether this lipid has a
role in modulating the pore formed by VP5. To address this, it
was assessed whether lower LBPA concentration could affect
the ability of 4-kDa dextran to be released from liposomes rel-
ative to the small molecule calcein. We performed a penetra-
tion assay utilizing LE liposomes loaded either with calcein or
FIGURE 6. Cholesterol accumulation in the late endosome inhibits BTV-1 infection. HeLa and PT cells were treated with 30 M of the late endosomal
cholesterol transport inhibitor U18666A (	I) before infection with BTV-1. Uninfected cells (M) or cells infected but untreated with the drug (V) were used for
comparison. A, non-structural proteins NS1 and NS2 were detected byWestern blotting in cells infected at MOI 5 (lanes 1–3 and 7–9) or MOI 1 (lanes 4–6
and 10–12). B, densitometry analysis of theWestern blotting expression data shown in A. C, quantification of virus titer by plaque assay (pfu/ml). Experiments
were performed in quadruplicate, and error bars represent S.D. Significant results are indicated (*, p  0.05). D, quantification of NS1 expression by immu-
noperoxidase assay. Resultswerenormalized toNS1expression frommock-treated infectedanduninfected cells. Non-significant (n.s.;p0.05) and significant
(*, p 0.05; **, p 0.01) results from three independent repeats are indicated. Error bars, S.D.
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4-kDa dextran, containing a titration of LBPA (Fig. 9B). For
each membrane composition, the release of 4-kDa dextran was
normalized to that of calcein for the same liposome composi-
tion. Interestingly, our results demonstrated that reducing the
content of LBPA of LE liposomes decreased the relative release
of 4-kDa dextran to calcein; this indirectly suggests, to some
extent, that membrane LBPA content could allow for VP5 pore
breathing or expansion.
Discussion
Both enveloped and non-enveloped virusesmust traverse the
limiting membrane barrier in the host cell in order to initiate
infection. This process demands interaction of the viral capsid
with the host membrane that modifies the target membrane
site. Enveloped viruses require fusion of their viral membrane
with that of the host, a process that has been well characterized
in both the viral protein components required (6, 51–54) and
the host lipid factors that allow membrane fusion (55–57). In
contrast to enveloped viruses, as yet, the lipid factors involved
in the process of non-enveloped virus membrane remodeling/
penetration remain poorly defined. The data presented here
demonstrate a role of the host lipid factor LBPA in mediating
host cell entry of the non-enveloped virus, BTV-1.
FIGURE7.Endocytosis of anti-LBPAantibody inhibitsBTV-1entry.HeLa cells
were treated with either anti-LBPA or anti-FLAG antibody before infection with
BTV-1. The expression of NS1 was quantified by an immunoperoxidase assay.
Results were normalized to NS1 expression inmock-infected cells. Significant (*,
p 0.05) results from three independent repeats are indicated. Error bars, S.D.
FIGURE 8. Cholesterol accumulation in the late endosome subsequent to BTV-1 infection does not inhibit virus replication. HeLa and PT cells were
infected with BTV before treatment with 30M U18666A (	I). Uninfected cells (M) or cells infected but untreated with the drug (V) were used for comparison.
A, expression of NS1 and NS2 proteins was detected byWestern blotting in cells infected at MOI 5 (lanes 1–3 and 7–9) or MOI 1 (lanes 4–6 and 10–12). B,
densitometry analysis of the Western blotting expression data from A. C, quantification of virus titer (PFU/ml). Error bars, S.D. values from four independent
experiments. Significant difference from control is indicated (*, p 0.05).
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Liposome assays strongly suggest that LBPApotentiates pore
formation by membrane penetration protein VP5 of BTV. The
physical properties of this lipid that allow such action were
delineated. Interrogation of physical factors of LBPA indicated
a combined role of both anionic charge and membrane fluidic
properties of this lipid. These properties appeared to be impor-
tant to facilitate the penetration activity of VP5. PS liposome
and mutant protein salt inhibition data suggest a model in
which an ionic charge interaction between conserved positive
charged residues of VP5N-terminal amphipathic helix and ani-
onic lipid may allow for initial membrane binding. However,
this is necessary but not sufficient for pore formation in more
complex liposome compositions, which more faithfully repre-
sent the makeup of cellular membranes encountered during
virus endocytosis. It seems that a threshold level of membrane
fluidity is also required for efficient VP5 pore formation, as
indicated by LBPA and cholesterol titration.
Pharmacological inhibition in cell culture supports the in
vitro model of membrane fluidity allowing BTV-1 entry and
reliance on LBPA to facilitate this. U18666A-mediated choles-
terol accumulation significantly decreases virus cell entry in
both the model HeLa cell line and a more biologically relevant
sheep-derived PT cell line. The exact effect of this inhibitor on
BTV entry will require further studies because it is plausible
that it may act to inhibit trafficking to the late endosomal com-
partment. Interestingly, U18666A has been shown to inhibit
the entry of enveloped dengue virus, which has also been shown
to rely on LBPA for cell entry from the late endosome (55, 58).
For BTV-1, the effect of such inhibition was most pronounced
at lower MOIs. Both enveloped and non-enveloped viruses
have been shown to enter host cells throughmultiple pathways
(59–62), the equilibrium of which may be shifted according to
the amount of incoming virus utilizing each host cell pathway.
It may be that at higherMOI, the major mode of host cell entry
is shifted to a pathway that bypasses the late endosome as this
pathway becomes saturated. BTV has been shown to enter cells
viamultiple pathways dependent on serotype. BTV-10 has been
demonstrated to enter mainly via a clathrin-mediated endocy-
tosis pathway (34), whereas BTV-1 has been implicated in uti-
lizing amacropinocytosismechanism (63). Amore recent study
with labeled virus using dynamin inhibition indicated that
BTV-1 also utilizes clathrin-mediated endocytosis (38). It may
be that the dynamic between these pathways is modulated by
the MOI of infection of host cells. Macropincytosis delivers
viral particles into macropinosomes, which traffic toward the
lysosome, with which it fuses eventually (64, 65). The lysosomal
membrane has also been shown to be enriched in LBPA (66),
and as such, BTVmay utilize this lipid at this site in the context
of macropinocytic entry.
AlongwithBTV, othermembers of theReoviridae also traffic
through to the LE and lysosomes for cell entry. Mammalian
orthoreovirus utilizes cathepsins of the late endosome to
uncoat and expose viral 1 protein for membrane penetration,
which may occur in this compartment (67). However, the lipid
components required to do so are not well characterized. Rota-
virus has been shown to rely on the endosomal sorting com-
plexes required for transport (ESCRT) machinery for host cell
entry, and in addition, this process can be blocked by preincu-
bating cells with an anti-LBPA antibody, strongly suggesting
that it too requires access to LBPA for efficient membrane pen-
etration (68). Given this, it seems that these complex non-en-
veloped viruses all require entry through the LE compartment.
Our in vitro pore size data suggest a mechanistic reasoning to
this observation, although more detailed studies will be
required to confirm this initial observation. From our results, it
appears that LBPA is able to allow the expansion of the pores
FIGURE 9. VP5 forms pores of a discrete size in late endosome-mimicking liposomes. A, late endosome-mimicking liposomes containing self-quenched
concentrations of calcein or fluorescent dextrans of the indicated sizes (in kDa) were tested in a pore formation assay. Results were normalized to 0.1% Triton
X-100-treated or -untreated liposomes. Significant differences are indicated (*, p  0.01 compared with calcein release). B, late endosomes containing a
decreasing amount of LBPA (swapped for PC) loaded with calcein or fluorescent 4-kDa dextran were tested in a pore formation assay. The release of 4-kDa
dextranwas normalized to that of calcein for liposomes of the samemembrane composition. Significant results from three independent repeats are indicated
(*, p 0.05; **, p 0.01). Error bars, S.D.
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produced from membrane penetration by VP5, and this
occurred in a concentration-dependent manner of LBPA. It
may be that the fluidic properties allow for breathing or expan-
sion of the pores formed during penetration. Hypothetically,
some viruses of the Reoviridae may require entry at the LE
compartment because the LBPA content of these membranes
allows for sufficient pore expansion upon penetration. This
fluid expansion would enable more efficient delivery of a large
core particle across the host cell membrane, thus initiating cell
infection. This generalization requires further studies and may
also provide a unique general therapeutic avenue for this virus
family.
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